The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

This expansion was made possible through collaboration with the Georgia Department of Economic Development, Invest Athens, Metro Atlanta Chamber, and Georgia Power. About Boehringer Ingelheim ...

With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Grand Opening of State-of-the-Art Research and Development Facility "Our new research and development facility in Athens marks ... Managing Director at Boehringer Ingelheim.

"Our new research and development facility in Athens marks a significant milestone ... U.S. Animal Health Country Managing Director at Boehringer Ingelheim. "Each year, we invest nearly 12 percent ...